---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-21-007741"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T11:07:28.944019+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Celldex reports Q3 net loss of $20.5M, cash $423M, CDX-0159 95% complete response.

## Summary
- Net loss $20.5M ($0.45/share) in Q3 2021; revenue $0.2M, vs net loss $14.2M ($0.36/share) in Q3 2020.
- Cash, cash equivalents & marketable securities $423.1M at Sept 30, 2021, up from $164M at June 30; cash runway through 2025.
- CDX-0159 Phase 1b in inducible urticaria: 95% complete response (18/19) after single dose; median response duration 77+ days (cold urticaria) and 57+ days (symptomatic dermographism).
- Completed $287.5M gross public offering in July 2021; net proceeds $269.9M.
- CDX-1140 combo with pembrolizumab shows confirmed partial response in head and neck cancer; ovarian expansion enrolling for CDX-527.

## SEC filing metadata
- accession: 0001171843-21-007741
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184321007741/0001171843-21-007741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184321007741/f8k_110921.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-21-007741
- JSON: https://secwatch.observer/filing/0001171843-21-007741.json
- Plain text: https://secwatch.observer/filing/0001171843-21-007741.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.